(Q42656263)

4 November 2017

Alzheimer's drug-development pipeline: 2016. (English)

1 reference

4 November 2017

0 references

1

Jeffrey Cummings

1 reference

4 November 2017

Travis Morstorf

2

1 reference

PMC publication ID

5651348

4 November 2017

Garam Lee

series ordinal

3

1 reference

4 November 2017

17 August 2016

1 reference

Alzheimer's & dementia (New York, N. Y.)

4 November 2017

1 reference

4 November 2017

2

1 reference

4 November 2017

4

1 reference

4 November 2017

222-232

1 reference

The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging

4 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5651348

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5651348

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5651348

PET Imaging of Tau Deposition in the Aging Human Brain.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5651348

2015 Alzheimer's disease facts and figures

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5651348

Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage ("Neuroprotection").

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5651348

Building a roadmap for developing combination therapies for Alzheimer's disease

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5651348

β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5651348

Alzheimer's disease drug-development pipeline: few candidates, frequent failures

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5651348

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5651348

Investigational drugs in Alzheimer's disease: current progress

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5651348

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5651348

A review: treatment of Alzheimer's disease discovered in repurposed agents

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5651348

Epidemiology of dementias and Alzheimer's disease.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5651348

The database for aggregate analysis of ClinicalTrials.gov (AACT) and subsequent regrouping by clinical specialty

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5651348

Alzheimer's disease: clinical trials and drug development

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5651348

Controversies in Alzheimer's disease drug development

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5651348

Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5651348

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5651348

16 August 2018

2015 FDA drug approvals

1 reference

Crossref

https://api.crossref.org/works/10.1016%2FJ.TRCI.2016.07.001

10.1016/J.TRCI.2016.07.001

7 January 2021

Identifiers

DOI

1 reference

4 November 2017

1 reference

PMC publication ID

5651348

4 November 2017

PubMed publication ID

29067309

1 reference

PMC publication ID

5651348